68 results on '"Lenting, Peter J."'
Search Results
2. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
3. Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs
4. How unique structural adaptations support and coordinate the complex function of von Willebrand factor
5. Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor
6. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
7. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
8. Antithrombin lowering in hemophilia: a closer look at fitusiran
9. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
10. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
11. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
12. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
13. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
14. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
15. Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
16. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
17. Laboratory monitoring of hemophilia A treatments: new challenges
18. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
19. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
20. von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week
21. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
22. Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement?
23. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support
24. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
25. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
26. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
27. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab
28. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
29. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
30. von Willebrand factor: from figurant to main character in the scene of inflammation
31. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia
32. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
33. Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein
34. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor
35. TaSER: Combining forces to stop the clot
36. Macrophage LRP1 contributes to the clearance of von Willebrand factor
37. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B
38. In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A
39. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF
40. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients
41. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo
42. Altered thrombus formation in von Willebrand factor–deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa
43. β2-Glycoprotein I inhibits von Willebrand factor–dependent platelet adhesion and aggregation
44. Emicizumab and thrombosis: The story so far
45. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B
46. LDL-receptor–related protein regulates β2-integrin–mediated leukocyte adhesion
47. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
48. Von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate
49. β2-Glycoprotein I and LDL-receptor family members
50. A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.